Meet Ideogen at EBMT 2027 in Rotterdam, 11–14 April, to discuss the latest advances in cell therapies and stem cell transplantation in oncohaematology.
Ideogen will be present at EBMT 2027 in Rotterdam to discuss the latest advances in cell therapies and stem cell transplantation, with a particular focus on oncohaematology. The 53rd Annual Meeting of the European Society for Blood and Marrow Transplantation takes place from 11–14 April 2027 at Rotterdam Ahoy.
We look forward to exchanging perspectives with the transplant and cellular therapy community: exploring emerging evidence, discussing unanswered questions and considering what scientific developments mean for the care of people with blood cancers.
Our focus will be on informed, non-promotional discussion of the science—not individual products or treatment recommendations.
The EBMT Annual Meeting brings together clinicians, researchers, nurses, pharmacists, laboratory scientists and other specialists involved in transplantation and cellular therapy. The organisers expect more than 6,000 participants, reflecting the meeting’s international and multidisciplinary scope. [web:14]
For Ideogen, this is an opportunity to listen as well as contribute: to understand the questions specialists are asking and discuss how evidence is developing across the transplant and cell therapy pathway.
We are particularly interested in conversations that connect scientific advances with the realities of specialist care, while recognising the uncertainty that accompanies emerging research.
The 2024 EBMT activity report, published in 2026, provides useful context for these discussions. It recorded 47,204 haematopoietic cell transplant procedures in 43,791 patients, reported by 688 centres across 53 countries.
The transplant total comprised 21,023 allogeneic procedures and 26,181 autologous procedures. These are procedure counts, not separate totals of unique patients.
The distinction matters: activity statistics describe how these approaches are being used, rather than demonstrating which treatment is best for an individual. They provide a starting point for questions about practice, patient selection and the evidence behind changing patterns of care.
Cellular therapies are an important part of the scientific conversation in blood cancers. The same EBMT report recorded 6,082 patients receiving CAR-T cell therapy in 2024, an increase of 24.5% compared with 2023; lymphomas, multiple myeloma and acute lymphoblastic leukaemia were prominent indications.
The research landscape extends beyond CAR-T. The EBMT Handbook also covers engineered T-cell approaches, gene editing and natural killer cell biology, providing a framework for discussing different directions in cellular therapy research.
At EBMT 2027, we will be interested in discussing how emerging evidence is evaluated: the durability of responses, the length of follow-up and the differences between clinical trial populations and patients treated in routine practice.
Our discussions will also consider the limitations of available evidence. A larger number of procedures does not, on its own, establish a clinical advantage or resolve questions about treatment sequencing.
Alongside cellular therapy, our conversations will explore developments in haematopoietic stem cell transplantation. The EBMT Handbook addresses donor selection, stem cell sources, conditioning, engraftment and immune reconstitution, illustrating the breadth of the transplant pathway. [web:60]
We want to discuss how research across these areas is shaping the questions transplant teams investigate, including donor availability, graft characteristics and recovery after transplantation.
The 2025 EBMT practice recommendations emphasise considering disease risk, procedural risk, other treatment approaches and local availability when applying recommendations. That context is essential to a balanced scientific discussion; no single approach should be presented as appropriate for every patient. [web:34]
Our interests extend beyond the transplant or cell infusion itself. The EBMT Handbook covers infection, graft-versus-host disease, graft failure, organ complications, long-term monitoring and quality of life as distinct areas of care. [web:60]
For CAR-T, recognised risks include cytokine release syndrome and neurological toxicity, which can be severe or life-threatening. Scientific discussion must consider these risks alongside evidence of benefit, rather than treating innovation as synonymous with safety. [web:49]
We will welcome discussion of how teams assess recovery, interpret follow-up findings and incorporate the patient’s experience into their understanding of outcomes.
Questions about survivorship deserve the same attention as questions about early response: what evidence is available over time, which outcomes are being measured, and where do important uncertainties remain? These are topics we hope to explore with the multidisciplinary community in Rotterdam.
Scientific progress also raises questions about how specialist services are organised. An EBMT analysis of treatment utilisation, based on 2022 activity data, identified substantial differences between countries in transplantation and CAR-T use, alongside associations with economic and demographic factors.
For Ideogen, these findings provide a reason to ask practical questions—not to assume that one health system’s experience applies everywhere.
We look forward to hearing perspectives on referral pathways, coordination between centres, evidence collection and the operational demands of specialist care. Our intention is to connect these discussions with the science, while keeping a clear distinction between research findings, clinical judgement and local service requirements.
We will be at EBMT 2027 to discuss the latest advances in cell therapies and transplantation in oncohaematology. We look forward to meeting colleagues, exchanging perspectives and learning from the questions shaping the field.
Delegates can explore the official scientific programme for current sessions and speakers; EBMT notes that programme details remain subject to change.
If you are attending, we would welcome the opportunity for a scientific conversation with the Ideogen team during the meeting.
